FOXO - CONSENSUS CO - FOXO Technologies

FOXO Technologies (FOXO) develops AI tools for determining biological age, although its current pricing power is limited due to a lack of broad medical recognition. This micro-cap biotech relies on the monetization of wellness services and epigenetic research, with the indicator standing at . This chart of the share price reflects the company's trajectory during its radical transition toward health IT analytics and digital biomarkers.

The consensus forecast represents the arithmetic mean of target prices from leading analysts, filtering out market noise to identify the asset's fundamental value. Investors should weigh the current consensus valuation against the adoption rate of epigenetic tests by the insurance sector and biometric regulatory risks, as the inertia of expert estimates may temporarily mask the capital shortfall required for the development of FOXO (FOXO) longevity algorithms.